Published in Acta Neuropathol Commun on October 09, 2013
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun (2014) 1.01
Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin (2013) 0.99
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. Neuroimage (2014) 0.97
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain (2015) 0.92
The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurol Sci (2016) 0.90
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement (2015) 0.90
Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology (2016) 0.88
Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology (2015) 0.88
The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement (2014) 0.87
Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. PLoS One (2014) 0.84
Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Eur J Nucl Med Mol Imaging (2015) 0.82
Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiol Aging (2015) 0.82
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci (2017) 0.82
Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis (2015) 0.82
Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathol (2015) 0.81
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology (2017) 0.81
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement (2015) 0.78
Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther (2014) 0.78
Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease. PLoS One (2014) 0.78
Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. Alzheimers Dement (2016) 0.76
Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimers Dement (2015) 0.76
A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol (2017) 0.75
Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis (2015) 0.75
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. J Int Neuropsychol Soc (2016) 0.75
Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease. Curr Genet Med Rep (2015) 0.75
Pattern of extrapyramidal signs in Alzheimer's disease. J Neurol (2015) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging (1997) 10.81
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Voxel-based morphometry using the RAVENS maps: methods and validation using simulated longitudinal atrophy. Neuroimage (2001) 4.58
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Focal cortical presentations of Alzheimer's disease. Brain (2007) 4.07
Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol (2012) 3.46
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord (2004) 2.97
The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging (1997) 2.72
Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol (2007) 2.66
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol (2006) 2.62
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain (2008) 2.34
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol (2005) 2.31
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav (2012) 1.97
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav (2012) 1.88
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem (2004) 1.84
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain (2013) 1.64
Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol (2010) 1.60
Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage (2011) 1.54
Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology (2005) 1.52
Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol (2008) 1.52
What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain (2006) 1.51
Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA (2012) 1.40
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology (2012) 1.35
Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology (1996) 1.32
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimers Dement (2010) 1.18
Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology (2012) 1.13
Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol (2007) 1.04
Selected findings from the Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis (2013) 1.03
Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest (2007) 1.03
Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn Disord (2011) 0.91
Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. J Neurol (2012) 0.88
A follow up study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies. J Neurol Sci (2013) 0.87
Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry (2011) 0.86
Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis (2013) 0.85
Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol (2013) 0.83
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
HAMMER: hierarchical attribute matching mechanism for elastic registration. IEEE Trans Med Imaging (2002) 12.71
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Thinning of the cerebral cortex in aging. Cereb Cortex (2004) 8.31
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci (2007) 7.31
Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci (2003) 7.26
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A (2003) 5.64
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord (2007) 5.01
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2009) 4.18
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87